INCR Intercure

InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market

InterCure CEO Alex Rabinovitch Purchases Over 420,000 Shares of Company Stock in The Open Market

NEW YORK, TORONTO and HERZLIYA, Israel, Oct. 12, 2021 (GLOBE NEWSWIRE) -- . (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) (dba Canndoc) ("InterCure" or the “Company”) today announced that CEO Alexander Rabinovitch purchased, throughout the month of September 2021, a total of 423,501 shares of the Company’s common stock.

Mr. Rabinovitch purchased the shares by buying 423,501 shares in the open market at an average price of USD$7.03 per share (CAD $8.95 or NIS 22.69). The shares were purchased partially on the NASDAQ and in part on the Tel Aviv Stock Exchange, for a total investment in the Company of USD$2,975,730 (CAD $3,790,238 per share or NIS 9,608,631).

About InterCure (dba Canndoc)

InterCure (dba Canndoc) (NASDAQ: INCR) (TSX: INCR.U) (TASE: INCR) is the leading, profitable, and fastest growing cannabis company outside of North America. Canndoc, a wholly owned subsidiary of InterCure, is Israel's largest licensed cannabis producer and one of the first to offer Good Manufacturing Practices (GMP) certified and pharmaceutical-grade medical cannabis products. InterCure leverages its market leading distribution network, best in class international partnerships and a high-margin vertically integrated "seed-to-sale" model to lead the fastest growing cannabis global market outside of North America.

For more information, visit: .

To be added to InterCure’s email distribution list, please email with “InterCure” in the subject.

Contact:

InterCure Ltd.

Amos Cohen, Chief Financial Officer

KCSA Strategic Communications

Investor and Media Relations

 



EN
12/10/2021

Underlying

INCRIntercure

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intercure

 PRESS RELEASE
Free
INCR INTERCURE

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requireme...

InterCure Receives Nasdaq Notification Regarding Minimum Bid Requirement NEW YORK and HERZLIYA, Israel, March 03, 2026 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR) (TASE: INCR) (“InterCure” or the “Company”) today announced that on February 25, 2026 the Company received a written notice (the “Notice”) from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(2), as the Company’s closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasda...

March 3, 2026 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Mill...

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash of NIS 43 Million InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the German...

February 19, 2026 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Mill...

InterCure Announces Preliminary Estimated 2025 Revenue of NIS 265 Million, Positive Adjusted EBITDA and Cash¹ of NIS 43 Million InterCure reports preliminary estimated revenue of NIS 265 million for 2025 and positive Adjusted EBITDA2, marking its twelfth consecutive half-year of positive Adjusted EBITDA. Revenue for 2025 represents an increase of approximately 11% compared to 2024, while revenue for the second half of 2025 is nearly 20% higher than the corresponding period in the prior year. During the second half of 2025, the Company generated its first significant revenues from the Germ...

February 19, 2026 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure and Cannasoul Sign Strategic Investment and Collaboration Ag...

InterCure and Cannasoul Sign Strategic Investment and Collaboration Agreements to Advance Cannabis Science and Pharmaceutical Innovation Agreements formalize research partnership combining InterCure’s global pharmaceutical platform with Cannasoul’s world-class analytics and scientific innovation Collaboration comes amidst reports that the Trump administration is exploring cannabis rescheduling, expected to create unprecedented opportunities in the U.S. for international operators like InterCure NEW YORK & HERZLIYA, Israel , Nov. 03, 2025 (GLOBE NEWSWIRE) -- InterCure Ltd. (Nasdaq: INCR...

November 3, 2025 1 EN
 PRESS RELEASE
Free
INCR INTERCURE

InterCure Reports First Half 2025 Results with NIS 130 Million in Reve...

InterCure Reports First Half 2025 Results with NIS 130 Million in Revenue and Positive Operating Cash Flow The Company reports NIS 130 million in revenue and NIS 12 million in positive operating cash flow, demonstrating resilience and sustained profitability with its eleventh consecutive half of positive Adjusted EBITDA amidst ongoing recovery in Israel InterCure is encouraged by recent regulatory momentum in the U.S. and believes that it is well positioned to capitalize on evolving U.S. cannabis rescheduling, especially following its recent signing of an agreement to acquire ISHI NEW YOR...

October 8, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch